JP2023518474A5 - - Google Patents
Info
- Publication number
- JP2023518474A5 JP2023518474A5 JP2022556583A JP2022556583A JP2023518474A5 JP 2023518474 A5 JP2023518474 A5 JP 2023518474A5 JP 2022556583 A JP2022556583 A JP 2022556583A JP 2022556583 A JP2022556583 A JP 2022556583A JP 2023518474 A5 JP2023518474 A5 JP 2023518474A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- disease
- kit
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2004094.5 | 2020-03-20 | ||
| GBGB2004094.5A GB202004094D0 (en) | 2020-03-20 | 2020-03-20 | New compounds and uses |
| PCT/GB2021/050674 WO2021186180A1 (en) | 2020-03-20 | 2021-03-18 | Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518474A JP2023518474A (ja) | 2023-05-01 |
| JP2023518474A5 true JP2023518474A5 (enExample) | 2024-03-28 |
| JP7773988B2 JP7773988B2 (ja) | 2025-11-20 |
Family
ID=70546543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556583A Active JP7773988B2 (ja) | 2020-03-20 | 2021-03-18 | アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230114153A1 (enExample) |
| EP (1) | EP4121047B1 (enExample) |
| JP (1) | JP7773988B2 (enExample) |
| CN (1) | CN115666557A (enExample) |
| CA (1) | CA3174437A1 (enExample) |
| GB (1) | GB202004094D0 (enExample) |
| WO (1) | WO2021186180A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3212900A1 (en) * | 2021-03-23 | 2022-09-29 | Tomas Fex | Selective angiotensin ii receptor ligands |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| EP4648850A1 (en) * | 2023-01-09 | 2025-11-19 | Vicore Pharma AB | Selective angiotensin ii compounds |
| AU2024331772A1 (en) * | 2023-08-25 | 2026-04-02 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Thienylsulfonyl carbamates as at2r agonists |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2096883A (en) * | 1933-07-19 | 1937-10-26 | Electrolux Corp | Vacuum cleaner |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| WO1994027597A1 (en) * | 1993-05-21 | 1994-12-08 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid angiotensin ii receptor antagonists |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| CN1529697B (zh) | 2001-05-31 | 2010-09-22 | 维科尔药物公司 | 用作血管紧张素ⅱ激动剂的三环化合物 |
| AU2003302106A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| US9864250B2 (en) * | 2014-11-14 | 2018-01-09 | Heliotrope Technologies, Inc. | Post-temperable nanocrystal electrochromic devices |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| EP3265082A1 (en) | 2015-03-02 | 2018-01-10 | Vicore Pharma AB | Angiotensin ii receptor agonist for treating pulmonary fibrosis |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| GB202006079D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) * | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| CA3249539A1 (en) * | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
-
2020
- 2020-03-20 GB GBGB2004094.5A patent/GB202004094D0/en not_active Ceased
-
2021
- 2021-03-18 WO PCT/GB2021/050674 patent/WO2021186180A1/en not_active Ceased
- 2021-03-18 EP EP21714661.2A patent/EP4121047B1/en active Active
- 2021-03-18 CN CN202180021097.2A patent/CN115666557A/zh active Pending
- 2021-03-18 US US17/912,645 patent/US20230114153A1/en active Pending
- 2021-03-18 JP JP2022556583A patent/JP7773988B2/ja active Active
- 2021-03-18 CA CA3174437A patent/CA3174437A1/en active Pending